Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Deferred Tax Liability (2016 - 2019)

Historic Non-Current Deferred Tax Liability for Niagen Bioscience (NAGE) over the last 4 years, with Q4 2019 value amounting to $218000.0.

  • Niagen Bioscience's Non-Current Deferred Tax Liability rose 5912.41% to $218000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $218000.0, marking a year-over-year increase of 5912.41%. This contributed to the annual value of $218000.0 for FY2019, which is 5912.41% up from last year.
  • As of Q4 2019, Niagen Bioscience's Non-Current Deferred Tax Liability stood at $218000.0, which was up 5912.41% from $137000.0 recorded in Q4 2018.
  • Over the past 5 years, Niagen Bioscience's Non-Current Deferred Tax Liability peaked at $413000.0 during Q1 2016, and registered a low of $137000.0 during Q4 2018.
  • For the 4-year period, Niagen Bioscience's Non-Current Deferred Tax Liability averaged around $262200.0, with its median value being $218000.0 (2019).
  • As far as peak fluctuations go, Niagen Bioscience's Non-Current Deferred Tax Liability tumbled by 6390.98% in 2017, and later soared by 5912.41% in 2019.
  • Over the past 4 years, Niagen Bioscience's Non-Current Deferred Tax Liability (Quarter) stood at $399000.0 in 2016, then plummeted by 63.91% to $144000.0 in 2017, then fell by 4.86% to $137000.0 in 2018, then soared by 59.12% to $218000.0 in 2019.
  • Its Non-Current Deferred Tax Liability was $218000.0 in Q4 2019, compared to $137000.0 in Q4 2018 and $144000.0 in Q4 2017.